Ronald Nahass, MD
Infectious Disease · Hillsborough, NJNPI 1023084928
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,510 of the $213,270 with a category attached, or 60.7%. 38 manufacturers reported payments, led by Gilead at 33.1% of the total. Reporting peaked in 2020 at $69,397 and has fallen 92.5% since, to $5,176 in 2025. Among infectious disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 787 payments — averaging $270.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$70K
- Viiv Healthcare Company$62K
- Integra Lifesciences Corporation$32K
- AbbVie$24K
- Janssen Research & Development, LLC$9K
- Merck$8K
- plus $7K from 32 others
Across 1,208 payments — averaging $4871.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$3.1M
- Merck$799K
- Janssen Research & Development, LLC$509K
- Insmed, Inc.$506K
- AbbVie$310K
- Alkermes, Inc.$287K
- plus $410K from 4 others
Across 5 payments — averaging $10,200 each. An ownership or investment interest held by the physician or an immediate family member.
- New Wave Endo-surgical Corp.$51K
What the payments were for
- Consulting fees$44,96121%
- Speaking & faculty fees$129,51061%
- Travel & lodging$24,72112%
- Food & beverage$13,8256%
- Education$2540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$213,270 in reported general payments places this provider in the 95th percentile of 334 infectious disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 14 | $450,680 |
| DovatoDolutegravir Sodium/Lamivudine | 103 | $343,502 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 51 | $212,405 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 49 | $185,309 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 44 | $175,113 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 40 | $157,030 |
| JulucaDolutegravir/Rilpivirine | 44 | $151,934 |
| DescovyEmtricitabine/Tenofov Alafenam | 55 | $138,672 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 16 | $105,352 |
| TivicayDolutegravir Sodium | 26 | $89,726 |
| PrezcobixDarunavir/Cobicistat | 26 | $64,482 |
| OzempicSemaglutide | 33 | $51,243 |
| IsentressRaltegravir Potassium | 24 | $50,700 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 13 | $46,344 |
| JardianceEmpagliflozin | 23 | $26,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Triumeq, Juluca, Tivicay | $62,488 | $742,192213 claims |
| GileadBiktarvy, Genvoya, Descovy, Vemlidy | $70,490 | $541,292161 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $232 | $450,68014 claims |
| Johnson & JohnsonPrezcobix, Complera | $271 | $110,82639 claims |
| Janssen Products, LPSymtuza | $296 | $105,35216 claims |
| Novo NordiskOzempic | $29 | $51,24333 claims |
| MerckIsentress | $8,366 | $50,70024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 infectious disease providers in New Jersey.
Other infectious disease in Hillsborough
- Robert SegalHillsborough$41K
- Rohit BhallaHillsborough$7K
- Jerry SheenHillsborough$6K
- Meena SeenivasanHillsborough$6K
- David HermanHillsborough$4K
- Nazar RaoofHillsborough$4K
- Keith GottesdienerRahway$2.1M
- Jihad SlimNewark$2.1M
- Maria SzabelaNewark$474K
- Christopher LucastiSomers Point$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.